secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001104659-24-060444
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax and Sanofi enter $500M upfront collaboration; Sanofi buys $68.8M in stock
--------------------------------------------------------------------------------

- $500M non-refundable upfront payment; up to $700M in milestones for COVID products.
- Additional milestones up to $200M per Adjuvant Product (first four); royalties mid-single to low-twenties percent.
- Sanofi acquires 6.88M shares at $10/share (~$68.8M) in private placement.
- Sanofi gets co-exclusive rights to commercialize Novavax's COVID vaccines globally from 2025/2026 season.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465924060444/0001104659-24-060444-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465924060444/tm2414089d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-060444

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer